Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration

Abstract

The results suggest that there is no clinically relevant difference in efficacy between peroral and intravenous administration of nimodipine in preventing DINDs or cerebral vasospasm following SAH.

Early prediction of delayed cerebral ischemia in subarachnoid hemorrhage based on quantitative EEG: A prospective study in adults

“…There were no procedure-related infarctions. All patients were treated with nimodipine (Kronvall et al, 2009).…”

Off-Label Use of Drugs and Devices in the Neuroendovascular Suite

“…31 Intra-arterial or intravenous use of verapamil, nimodipine (Nimotop), and nicardipine (Cardene; Baxter Healthcare, Deerfield, Illinois) have all been reported to be effective and safe in the treatment of cerebral vasospasm (category III). 10,[32][33][34][35] The offlabel use of calcium channel blockers in treating cerebral vasospasm is recognized as a generally accepted medical practice within the physician community; however, the treating physician must ensure that adequate hemodynamic monitoring is performed on patients receiving these agents. Low doses of intraarterial calcium channel blockers were not associated with significant hemodynamic changes, but high-dose nicardipine was associated with hypotension.…”

Intravenous Versus Enteral Nimodipine in Aneurysmal Subarachnoid Hemorrhage: Is There an Advantage?

“…Between the present study by Soppi et al and the work by Kronvall et al (7) 277 patients have been randomized to compare intravenous versus enteral nimodipine. Collectively, no difference in any outcome measure has been demonstrated.…”